JP2023501317A5 - - Google Patents

Info

Publication number
JP2023501317A5
JP2023501317A5 JP2022525916A JP2022525916A JP2023501317A5 JP 2023501317 A5 JP2023501317 A5 JP 2023501317A5 JP 2022525916 A JP2022525916 A JP 2022525916A JP 2022525916 A JP2022525916 A JP 2022525916A JP 2023501317 A5 JP2023501317 A5 JP 2023501317A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
cell lymphoma
formula
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525916A
Other languages
English (en)
Japanese (ja)
Other versions
JP7575454B2 (ja
JP2023501317A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/080493 external-priority patent/WO2021089419A1/en
Publication of JP2023501317A publication Critical patent/JP2023501317A/ja
Publication of JP2023501317A5 publication Critical patent/JP2023501317A5/ja
Application granted granted Critical
Publication of JP7575454B2 publication Critical patent/JP7575454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525916A 2019-11-04 2020-10-30 B細胞悪性腫瘍を処置するためのアカラブルチニブとカピバセルチブとの治療的組み合わせ Active JP7575454B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930208P 2019-11-04 2019-11-04
US62/930,208 2019-11-04
PCT/EP2020/080493 WO2021089419A1 (en) 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Publications (3)

Publication Number Publication Date
JP2023501317A JP2023501317A (ja) 2023-01-18
JP2023501317A5 true JP2023501317A5 (cg-RX-API-DMAC7.html) 2023-10-13
JP7575454B2 JP7575454B2 (ja) 2024-10-29

Family

ID=73043259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525916A Active JP7575454B2 (ja) 2019-11-04 2020-10-30 B細胞悪性腫瘍を処置するためのアカラブルチニブとカピバセルチブとの治療的組み合わせ

Country Status (14)

Country Link
US (1) US12691113B2 (cg-RX-API-DMAC7.html)
EP (1) EP4054582B1 (cg-RX-API-DMAC7.html)
JP (1) JP7575454B2 (cg-RX-API-DMAC7.html)
KR (1) KR102984130B1 (cg-RX-API-DMAC7.html)
CN (1) CN114728003B (cg-RX-API-DMAC7.html)
AU (1) AU2020381240C1 (cg-RX-API-DMAC7.html)
CA (1) CA3158321A1 (cg-RX-API-DMAC7.html)
DK (1) DK4054582T3 (cg-RX-API-DMAC7.html)
ES (1) ES3055126T3 (cg-RX-API-DMAC7.html)
FI (1) FI4054582T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022005250A (cg-RX-API-DMAC7.html)
PL (1) PL4054582T3 (cg-RX-API-DMAC7.html)
PT (1) PT4054582T (cg-RX-API-DMAC7.html)
WO (1) WO2021089419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024104561A1 (en) * 2022-11-15 2024-05-23 Astrazeneca Ab Therapeutic combinations of capivasertib and venetoclax

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
AU2014360537B2 (en) * 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
EP3076974A1 (en) * 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
JP6785804B2 (ja) * 2015-06-23 2020-11-18 ギリアド サイエンシズ, インコーポレイテッド B細胞悪性腫瘍を治療するための組合せ療法
US20170071962A1 (en) 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
BR112017002594A2 (pt) * 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
AU2018335617B2 (en) * 2017-09-25 2021-12-09 Astrazeneca Ab Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
KR20250119664A (ko) 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정

Similar Documents

Publication Publication Date Title
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
EP1339399B1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
JP2012500180A5 (cg-RX-API-DMAC7.html)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2014132009A5 (cg-RX-API-DMAC7.html)
WO2010081817A1 (en) Method for treating colorectal cancer
US7846913B2 (en) Compositions and methods to treat recurrent medical conditions
TW202333675A (zh) 用於治療癌症之組合療法之用途
CN110013478A (zh) 用于抗肿瘤试剂施用的方法
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
JP2024542984A5 (cg-RX-API-DMAC7.html)
JP2010538066A5 (cg-RX-API-DMAC7.html)
JP2024517085A5 (cg-RX-API-DMAC7.html)
JP2023522415A5 (cg-RX-API-DMAC7.html)
HUP0204139A2 (en) Use of n-[6-methoxi-5-(2-methoxiphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2phenyl-etienesulfonamide for producing pharmaceutical composition using for reducing pain in an endothelin-induced disease
CN105101968A (zh) 治疗增殖性疾病的组合疗法
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
US20080207644A1 (en) Therapeutic materials and methods
JP7824627B2 (ja) 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物
FI4054582T3 (fi) Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon
JP2006508118A5 (cg-RX-API-DMAC7.html)
CA2672716A1 (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
CN100553634C (zh) 用于治疗多发性骨髓瘤的埃坡霉素衍生物
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
RU2320344C2 (ru) Применение 4-пиридилметилфталазинов для лечения рака